biosimilar medicines

Advancements in regulatory science support **streamlined biosimilar development already today.**[2]

Streamlining development can **reduce treatment costs**, relieve pharmaceutical budgets, allowing **reinvestment** in other health products and services.[4]

Current mandate for comparative efficacy studies acts as a **barrier to greater patient access.**[3]

Convergence of regulatory requirements can accelerate streamlined biosimilar development adoption.[5]

1 https://biosimilarscouncil.org/resource/streamlining-the-development-of-biosimilar-medicines/
2 Schiestl et al. BioDrugs 2020 https://doi.org/10.1007/s40259-020-00422-1
3 IQVIA Report Biosimilar Void (2023)
4 Biosimilars Report Bolsters IGBA's Calls To Streamline Development Process
5 Comparative efficacy studies of biosimilars: data versus theoretical risks, beliefs, and comfort

medicines for europe
better access. better health.